PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Lung Cancer10.1016/s0169-5002(09)70270-3200964S62147PD A PHASE II STUDY OF WEEKLY PACLITAXEL PLUS GEMCITABINE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SMALL CELL LUNG CANCER (SCLC)H.T. Kim, T. Yun, J. Han, H.L. Choi, H.Y. Kim, J.S. Leehttps://api.elsevier.com/content/article/PII:S0169500209702703?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500209702703?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2015.0612016482465-472A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung CancerTak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Leehttp://e-crt.org/upload/pdf/crt-2015-061.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2015.061, http://www.e-crt.org/upload/pdf/crt-2015-061.pdf
Lung Cancer10.1016/j.lungcan.2003.11.0062004442231-239Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancerGiovanni Luca Ceresoli, Vanesa Gregorc, Stefano Cordio, Katia Bruna Bencardino, Stefano Schipani, Cesare Cozzarini, Roberto Bordonaro, Eugenio Villahttps://api.elsevier.com/content/article/PII:S0169500203005920?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203005920?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(05)81078-5200549S272P-585 Carboplatin plus gemcitabine followed by weekly paclitaxel inadvanced and metastatic non-small cell lung cancer (NSCLC): A phase II studyV. Tjan-Heijnen, J. Timmer-Bonte, M. van der Drift, F. van Leeuwen, T. de Boo, M. Wagenaar, L. van Die, J. Bussinkhttps://api.elsevier.com/content/article/PII:S0169500205810785?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500205810785?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(98)90119-2199821S49Phase II trial of gemcitabine as second line therapy for non-small cell lung cancer (NSCLC)HH Gillenwater, M Tynan, MA Socinskihttps://api.elsevier.com/content/article/PII:S0169500298901192?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500298901192?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(95)98754-x1995123277A phase II study testing weekly platinum derivative combination chemotherapy as second-line treatment in patients with advanced small cell lung cancerhttps://api.elsevier.com/content/article/PII:016950029598754X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016950029598754X?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-008-0846-z200864173-78A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancerKiyoshi Mori, Hiroyuki Kobayashi, Yukari Kamiyama, Yasuhiko Kano, Tetsuro Kodamahttp://link.springer.com/content/pdf/10.1007/s00280-008-0846-z.pdf, http://link.springer.com/article/10.1007/s00280-008-0846-z/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-008-0846-z
Chemotherapy10.1159/000335601201258178-83A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung CancerKiyoshi Mori, Yukari Kamiyama, Hisashi Kasai, Tetsuro Kodamahttps://www.karger.com/Article/Pdf/335601, http://www.karger.com/Article/Pdf/335601
European Journal of Cancer Supplements10.1016/s1359-6349(07)71444-12007543936616 POSTER Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapyK. Mori, Y. Kamiyama, T. Kondo, T. Kodamahttps://api.elsevier.com/content/article/PII:S1359634907714441?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634907714441?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-006-0360-02006602189-195Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapyKiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano, Tetsuro Kodamahttp://link.springer.com/content/pdf/10.1007/s00280-006-0360-0.pdf, http://link.springer.com/article/10.1007/s00280-006-0360-0/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-006-0360-0